Treating Immune-Mediated, Inflammatory Diseases with Janus Kinase (JAK) Inhibitors
Learning objectives:
Target Audience:
This educational initiative is targeted towards rheumatologists, advanced practice providers, nurses, rheumatology trainees, and other ancillary clinicians who treat and manage patients with Janus kinase inhibitors.
Estimated time to complete the educational activity:
4 hours, 45 minutes
Dates of the original release and the termination date of the activity:
June 20, 2024 - June 19, 2025
The principal faculty and their credentials:
Leonard Calabrese, DO
Head, Clinical Immunology, Co-Director of the Center for Vasculitis Care and Research
Cleveland Clinic
Sonali Khandelwal, MD (Course Director)
Associate Professor, Department of Internal Medicine, Division of Rheumatology
Rush Medical College
Brooke Kimmel, PharmD
Rush University Medical Center
Chicago, IL
M. Elaine Husni, MD, MPH
Vice Chair of Rheumatology, Director, Arthritis and Musculoskeletal Center
Cleveland Clinic
Disclosure Information:
It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.
The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
Individuals in control of content for this activity have the following relevant financial relationships to disclose.
|
Name of individual |
Disclosure |
|
Leonard Calabrese, DO |
Consultant: AbbVie, Jansen, UCB, Sanofi, AstraZeneca, Amgen |
|
Sonali Khandelwal, MD |
None |
|
Brooke Kimmel, PharmD |
None |
|
M. Elaine Husni, MD, MPH |
Consultant/Advisory Board: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB Royalty: PASE Tool – patient reported questionnaire |
All of the relevant financial relationships listed for these individuals have been mitigated. The remaining course director(s), planner(s), faculty and reviewer(s) of this activity have no relevant financial relationship(s) with ineligible companies to disclose.
Accreditation Statement & Designation Statement
Accreditation Statement:
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Joint Providership Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Rush University Medical Center and RealCME. Rush University Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statements
For Medicine:
Rush University Medical Center designates Blended activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
For Nursing:
Rush University Medical Center designates this Blended Activity for a maximum of 4.75 nursing contact hour(s).
For Pharmacy:
Rush University Medical Center designates this knowledge-based Blended Activity for a maximum of 4.75 contact hour(s) for pharmacists. UAN# JA0000275-9999-24-292-H01-P
Unapproved Uses of Drugs/Devices:
In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
Acknowledgement of Support:
This activity is funded in part by an unrestricted grant from AbbVie Inc.
Method of participation in the learning process:
This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all assessment questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.
In order to claim the maximum amount of credit available, you must complete all of the following:
Partial credit will not be awarded for CME/CNE/CPE; participation in the complete activity is required to receive credit.
Physicians/Nurses who successfully complete all the components of the educational activity and the course evaluation will receive CME/CNE credit.
Pharmacists who successfully complete all the components of the educational activity and the course evaluation will receive pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks after successfully completing the different components of the course, and course evaluation.
All other participants who successfully completed the course in its entirety and the course evaluation will receive a certificate of participation.
